Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08ZAC
|
|||
Drug Name |
ICAR30 T cells
|
|||
Drug Type |
CAR T Cell Therapy
|
|||
Indication | Anaplastic large cell lymphoma [ICD-11: 2A90.A; ICD-10: C84.6] | Phase 1 | [1] | |
Hodgkin lymphoma [ICD-11: 2B30; ICD-10: C81, C81.9] | Phase 1 | [1] | ||
Company |
Immune Cell, Inc.
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Lymphocyte activation antigen CD30 (TNFRSF8) | Target Info | CAR-T-Cell-Therapy | [1] |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
NetPath Pathway | Leptin Signaling Pathway | |||
TCR Signaling Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03383965) CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.